SCHEMBL514540

SCHEMBL514540

COCOC(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
TSHR P16473 2/20 0.59
TDP1 Q9NUW8 3/20 0.59
SLC6A3 Q01959 2/20 0.57
MAPK1 P28482 1/20 0.57
HIF1A Q16665 1/20 0.57
SLC6A2 P23975 1/20 0.57
KMT2A Q03164 1/20 0.57
ALDH1A1 P00352 2/20 0.55
F2 P00734 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
GAA P10253 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
ADRB2 P07550 1/20 0.47
ADRB1 P08588 1/20 0.47
ADRB3 P13945 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14287513 0.93 LMNA (0.53) LMNATSHRTDP1SLC6A3MAPK1
SCHEMBL11358478 0.93 LMNA (0.53) LMNATSHRTDP1SLC6A3MAPK1
P-Xylene SCHEMBL28048503 0.93 NPC1 (0.63) LMNATSHRTDP1SLC6A3MAPK1
SCHEMBL29104383 0.89 TDP1 (0.66) LMNATSHRTDP1SLC6A3MAPK1
SCHEMBL14898425 0.89 ESR1 (0.52) LMNATSHRTDP1MAPK1SLC6A2
SCHEMBL27914437 0.89 KDM4E (0.60) LMNATSHRTDP1KMT2AALDH1A1
SCHEMBL28875175 0.87 TDP1 (0.68) LMNATSHRTDP1SLC6A3MAPK1
SCHEMBL51601 0.87 TDP1 (0.68) LMNATSHRTDP1SLC6A3MAPK1
SCHEMBL15397149 0.86 MAPT (0.54) LMNATSHRTDP1SLC6A2ALDH1A1
SCHEMBL27796834 0.83 LMNA (0.61) LMNATSHRTDP1SLC6A3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3375883-B1 METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE AJINOMOTO KK (JP) 2021-02-03 EP claimed
US-10266857-B2 Method for producing Nε-acyl-L-lysine AJINOMOTO CO., INC. (JP) 2019-04-23 US claimed
EP-3375883-A1 METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE Ajinomoto Co., Inc. (JP) 2018-09-19 EP claimed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-20230293569-A1 MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-09-21 US disclosed
US-20230158053-A1 NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES METROBIOTECH, LLC 2023-05-25 US disclosed
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 US disclosed
WO-2023066359-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2023-04-27 WO disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
EP-3375883-B1 METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE AJINOMOTO KK (JP) 2021-02-03 EP disclosed
WO-2020011147-A1 RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-01-16 WO disclosed
US-20070049696-A1 Reacting a acrylic and vinyl monomer in presence of free radical catalyst CID CENTRO DE INVESTIGACION Y DESARROLLO TECNOLOGICO SA DE CV (MX) 2007-03-01 US disclosed
CN-1128783-C Process for distillation of crude ester in DMT/PTA process DEGUSSA (DE) 2003-11-26 CN disclosed
CN-1106385-C Substituted 4-benzoyl-pyrazoles BASF AG (DE) 2003-04-23 CN disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
CN-1247532-A Substituted 4-benzoylpyrazoles BASF AG (DE) 2000-03-15 CN disclosed
CN-1245488-A Substituted 2-benzoyl-cyclohexan-1,3-diones with herbicidal effect BASF AG (DE) 2000-02-23 CN disclosed
US-5859143-A BLOCK COPOLYMERIZATION REACTION IN PRESENCE OF HYDROGEN AND STEREOSPECIFIC CATALYST CONTAINING COMPOUNDS OF MAGNESIUM, TITANIUM, HALOGEN, ORGANOALUMINUM AND ELECTRON DONOR MITSUBISHI CHEMICAL CORPORATION (JP) 1999-01-12 US disclosed
CN-1176847-A Catalyst and method for catalytic off-gas cleaning in DMT process HUELS CHEMISCHE WERKE AG (DE) 1998-03-25 CN disclosed
CN-1172101-A Process for distillation of crude ester in DMT/PTA process HUELS CHEMISCHE WERKE AG (DE) 1998-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158053-A1 NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES NAMPT, NNT, NQO1 LMNA 603/4885TSHR 3861/4885TDP1 2917/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 LMNA 1211/4885TSHR 3767/4885TDP1 298/4885
US-20230293569-A1 MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME NAMPT, NUDT15, NME4 LMNA 787/4885TSHR 3809/4885TDP1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.